Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, January 29, 2015
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

HOMOGENEOUS ADCs BEARING TWO DIFFERENT PAYLOADS SHOW STRONG SYNERGY IN TUMOR KILLING
Lisha Allen, Yi Mi, Muhammad Abbas, Wolfgang Richter, and Sean Hu

We presented a one-pot reaction to prepare site-specific ADCs using available mABs on hand without re-engineering. We have identified a novel non-cleavable linker, which increases not only ADC stability, but also potency. We also demonstrate synergy in cancer cell killing of hybrid ADC loaded with two different toxins

More information
Toward a Comprehensive Bottom-up and Top-down Analysis of the NIST Reference Monoclonal Antibody
Chris Becker1, Eric Carlson1, Wilfred Tang1, Yong Kil1, Marshall Bern1, John Schiel2, Lisa Kilpatrick2, Trina Formolo2

Development of ADC and other therapeutic proteins require careful characterization of sequence, post-translational modifications, sequence variants, and degradants. In this study, a NIST mAb interim reference material was analyzed by new bioinformatics tools (Byonic™, Byologic®, and Byomap™) allowing one to efficiently identify and quantify modifications down to trace levels.

More information
Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors
T. Roux1, M. Badol1, N. Douayry1, L. Sergeant1, E.Trinquet1, F. Degorce1, S. Milhas2, S. Betzi2, C. Derviaux2, C. Eydoux3, J. Letienne2, A. Lugari2, Y. Collette2, J-C. Guillemot3 et X. Morelli2

Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.

More information
Artificial Multi-Gene Expression Systems Design Service for Natural Compound Formation and Hetero Protein Complexes
Bernauer, Hubert, Gregor Zipf and Josef Maier

Drug discovery of natural compounds drug development and drug target analyses as well as bioproduction can benefit from artificial genetic systems and constructions. The direction in which genes are to be developed is written in the genomes. Synthesis oriented genomic analyses of codon bias and tRNA adaption analyses are prerequisites for generating adaptive, highly functional genes.

More information
Next Generation Multivalent PRINT Nanoparticle Vaccine Targeting Pneumococcal Disease
Shyam Rele,1 RiLee Robeson,1 Anton Beletskii,1 Jeremy Hansen,1 Meredith Earl,1 Gabe Fawcett,1* Marquita Lilly,1 Joseph Marchand,1 Michele Stone,1 Camille Bernasconi,1 Jinny Conley,1 Michael Hunter,1 Ramya Yadavalli,1 Nicole Meyer,1 Lara Kelly,1 Ben Yerxa,1 Jeff Maisonneuve,2 Mark Alderson,2 Frank Malinoski1

A new generation PRINT nanoparticle Pneumococcal vaccine matrix has been designed to mimic size and structural aspects of bacterial pathogens to efficiently present and deliver polysaccharide and protein antigens to elicit robust immune responses.

More information
Factors influencing mAb aggregation in mammalian cell culture
Albert Paul, Melanie Leitte, Franziska Schandock, Rene Handrick and Friedemann Hesse

Analysis of mAb aggregate formation in Chinese hamster ovary (CHO) cell culture.

More information
Developing Functional Monoclonal Antibodies for Beta-3 Adrenergic Receptor
Miao Tan and Helena Mancebo

Our preliminary data showed that several mAb clones specifically bound to the receptor while increasing the receptor function by acting as agonists.

More information
Early Immunogenicity Risk Mitigation
Chloé Ackaert, Brecht Hoedemaekers, Sofie Pattijn and Philippe Stas

The ability of a drug candidate to induce an unwanted immune response can be a significant hurdle during drug development and a reason for product failures. Unwanted immunogenicity can cause loss of efficacy, altered pharmacodynamics and stability problems. .

More information
MAB Discovery Technology: A Smart Way to Highly Diverse and Functional Therapeutic Antibodies
Hans-Willi Krell

MAB Discovery GmbH developped a highly integrated process which provides diverse antibodies by starting with a high number of B cells and filtering the relevant antibodies by an early-on functional screening.

More information
A Rapid and Effective Tool for Monitoring Monoclonal Antibody Production
B. Bhullar, Ph.D., Carlina Hui, B.Sc., M. Hariharan, M.Sc., J. Hewitt, B.Sc , and N. Vats, Ph.D.

Monoclonal antibodies (Mab) are used in a variety of fields from diagnostics to therapeutics. Manufacturers of in vitro diagnostics (IVD) commonly use third-party suppliers to meet their needs for specified monoclonal antibodies.

More information
<< 1 2 3 >>
Showing Results 1 - 10 of 26
Scientific News
Beating The Clock: New Treatment For Rabies Developed
University of Georgia researchers have developed a new treatment for rabies.
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
New Approach May Lead to Inhalable Vaccines
The approach using nanoparticles could lead to development of inhalable vaccines for influenza, pneumonia and tuberculosis.
New Mouse Study Method Enables Comparative Vaccine Studies for Tularemia
The study appears online in Clinical Vaccine and Immunology.
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
UMMS Receives $6.1 M to Develop Model for Predicting Gene Expression
Insight into regulation of the genes that allow the immune system to recognize pathogens will help scientists rationally design new vaccines and prevent autoimmunity.
GRP78 Protein Possible Universal Therapeutic Target
Drug combination including Viagra is effective tool in targeting the protein.
Adapting Influenza for Vaccine Mass Production
The ability to grow influenza in cell culture rather than chicken eggs paves the way for mass production of the vaccine.
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Closing in on ‘Holy Grail’ of HIV Vaccine
Researchers describe a way to induce long-sought broadly neutralizing antibodies.
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn